We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AD Biomarkers in Ocular Fluid Indicate Dementia Risk

By LabMedica International staff writers
Posted on 25 Mar 2019
Measuring levels of amyloid-beta and tau proteins in the eye's vitreous humor has been suggested as means to detect dementia at an early stage in individuals at risk for Alzheimer's disease (AD).

Investigators at the Boston Medical Center (MA, USA) determined levels of amyloid-beta (Abeta) and tau protein in human vitreous humor and evaluated the clinical predictive role of these proteins as early diagnostic markers of AD.

For this study, vitreous humor samples from 80 eyes were measured quantitatively for Abeta42, pTau, and tTau. More...
Linear regression was used to test associations between AD biomarker levels, Mini-Mental State Exam (a baseline cognitive test), and serum apolipoprotein E (APOE) allele status, with adjustment for age, sex, and education level of patients.

Results revealed that patients with poor cognitive function had significantly lower vitreous humor levels of the AD-related biomarkers Abeta40, Abeta42, and tTau. Levels of these biomarkers did not correlate with underlying eye conditions, suggesting their specificity in association with cognitive change. This was perhaps the first study to correlate cognition with AD-related proteins in the vitreous humor. Results suggested that ocular proteins may have a role for early dementia detection in individuals at risk for AD.

"This is a great step in discovering the eye's potential role in diagnosing preclinical Alzheimer's disease, and further study is needed comparing protein biomarkers in the eye with more in-depth neurological testing," said senior author Dr. Manju Subramanian, associate professor of ophthalmology at Boston Medical Center.

The study was published in the March 8, 2019, online edition of the Journal of Alzheimer's Disease.

Related Links:
Boston Medical Center


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.